| Date | Title | Description |
| 24.12.2025 | TargED: €21.5 Million Series A Extension Raised To Advance Targeted Thrombolytic TGD001 | TargED Biopharmaceuticals B.V., a clinical-stage biotech company developing targeted treatments for thrombotic diseases, has closed a €21.5 million Series A extension led by BioGeneration Ventures (BGV). Existing investors, including Andera... |
| 20.10.2025 | Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London | PISCATAWAY, N.J., Oct. 20, 2025 /PRNewswire/ -- London will become the global spotlight for cell and gene therapy (CGT) this November as Nobel Laureate, scientific leaders, biotech innovators, and top investors convene to chart the future o... |
| 16.09.2025 | EQT Life Sciences portfolio company VarmX partners with CSL in a strategic collaboration and option agreement worth up to USD 2.2 billion | EQT Life Sciences portfolio company VarmX partners with CSL in a strategic collaboration and option agreement worth up to USD 2.2 billion
Tue, Sep 16, 2025 14:00 CET Report this content
VarmX is developing a bypass agent to restore coagulat... |
| 16.09.2025 | CatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development | Experienced executives, Clinton Musil, Sujata Rao, MD, Heike Krupka, PhD, and Andrea Goddard join CatalYm to broaden and accelerate clinical programs into late-stage development
Munich, Germany and San Francisco, USA, September 15, 2025 – C... |
| 12.08.2025 | AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease | MILAN, August 12, 2025 — AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has gr... |
| 28.07.2025 | Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively | • First patient dosed in global pivotal clinical trial program for late infantile/juvenile onset NPC and GM1/GM2 gangliosidoses.
• Both studies are part of Azafaros’ mission to develop treatments for the unmet need of patients with rare lys... |
| 30.06.2025 | Forbion Announces Fifth Exit from Forbion Growth Opportunities Fund II with the Sale of Capstan Therapeutics to AbbVie for USD 2.1 Billion | • Capstan sale ranks as the largest ever payment for an early-stage private biotech company by upfront consideration value and is Forbion’s seventh consecutive >$1B exit.
• Capstan’s in vivo CAR-T platform offers a first-in-class approac... |
| 12.05.2025 | Bio€quity Europe 2025 | The 25th Bio€quity Europe takes place at the Bruges Meeting & Convention Centre (BMCC) from 12 - 14 May 2025. On 13 May, Managing Partner Dirk Kersten will take part in the session "Growth Capital: Essential Pillars for the Europea... |
| 15.04.2025 | The 2025 Cell & Gene Meeting on the Med | The 2025 Cell & Gene Meeting on the Med
15 - 17 April, Rome, Italy
The Cell & Gene Meeting on the Mediterranean is the leading conference bringing together the ATMP community from Europe and beyond.
Forbion Senior Associate Tim Loho... |
| 23.02.2025 | 18th Annual European Life Sciences CEO Forum | The 18th Annual European Life Sciences CEO Forum (#Sachs_ELSF) will take place on the 26th - 27th of February 2025 at the Hilton Zurich Airport Hotel. The main programme for the 18th Annual ELSF is spread over 2 days (26th - 27th of Februar... |
| 28.01.2025 | IPEM | Since 2016, IPEM Cannes has brought a different essence to the private capital industry by gathering its key decision-makers in a conducive environment for meaningful exchanges. With its vibrant ecosystem, IPEM Cannes and the brand-new even... |
| 15.01.2025 | RhyGaze raises CHF 86 million to advance gene therapy for retinal diseases |
RhyGaze was founded on intellectual property exclusively licensed to the company by the Institute of Molecular and Clinical Ophthalmology Basel (IOB), a scientific institute led by Director Botond Roska, who is a scientific co-founder of R... |
| 28.12.2024 | SACHS Associates - 1st BioPharma Obesity Innovation Forum for Science, Drug Development, Technology and Investment | Principal Antoine Boulanger will co-chair the Investor Roundtable at the Sachs Associates 1st BioPharma Obesity innovation Forum. Click here to access the agenda and to learn about registering for this event. |
| 12.12.2024 | Dutch Life Sciences Conference - Leiden | The Dutch Life Sciences Conference takes place on December 12, 2024 at Leiden Bio Science Park. Managing Partner Sander Slootweg will take part in the afternoon panel "The Road to IPO." Click here for more information about ticket... |
| 10.12.2024 | Citryll's €85 Million Boost: A New Dawn for Inflammatory Disease Treatment | In the world of biotech, funding is the lifeblood. Recently, Dutch startup Citryll secured a significant €85 million in Series B funding. This financial windfall is not just a number; it represents hope for countless patients battling immun... |
| 09.12.2024 | Oss-based Citryll secures €85 million Series B funding to advance NET-targeting therapy | Dutch startup Citryll, a biotech innovator in immune-mediated inflammatory diseases, has raised €85 million in a Series B funding round.
The financing was co-led by Johnson & Johnson Innovation (through its corporate venture capital org... |
| 02.12.2024 | Forbion, in collaboration with members of the EU Life Sciences ESG Knowledge Project release 2025 questionnaire | Forbion is proud to be a signatory and active member of the EU Life Sciences ESG Knowledge Project, a pioneering initiative supported by Impact House by Grant Thornton. This project unites 22 Life Science investors in developing a coordinat... |
| 29.09.2024 | World Agri-Tech Innovation Summit | 29 September - 01 October, London
The World Agri-Tech Innovation Summit in London is the leading European networking event, uniting over 1000 business leaders and key stakeholders dedicated to driving advancements in climate-resilient, sust... |
| 26.09.2024 | Forbion Head of Impact & ESG named as one of Top 50 Women in Sustainable Finance 2024 | Forbion's Head of Impact and ESG, Silva Dezelan, PhD has been named as one of the Top 50 Women in Sustainable Finance by WIFS The Netherlands. The list highlights female leaders in the Netherlands who are committed to sustainability within ... |
| 25.09.2024 | Tanai Therapeutics secures additional financing from Novo Nordisk and BioGeneration Ventures for novel obesity drug | Ghent, Belgium, 19 September 2024 – Tanai Therapeutics (“the Company” or “Tanai”), a VIB spin-off company developing a new therapeutic class of obesity treatments, today announces it has secured additional financing from Novo Nordisk A/S an... |
| 28.07.2024 | The Surge of Innovation: How Magenta Medical and Brenig Therapeutics are Shaping the Future of Healthcare | In the world of healthcare, innovation is the lifeblood that keeps the industry thriving. Two companies, Magenta Medical and Brenig Therapeutics, are at the forefront of this revolution. With significant funding rounds recently completed, t... |
| 26.07.2024 | Brenig Therapeutics: Neurology-Focused Drug Development Company Secures $65 Million In Series A | Brenig Therapeutics – a neurology-focused drug development company utilizing an AI/ML-based discovery platform – announced the closing of a $65 million Series A funding.
The funding was led by New Enterprise Associates (NEA) with support fr... |
| 12.03.2024 | Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients | Major milestone reached in bringing new treatment options to patients and their families
Leiden, The Netherlands, March 12, 2024 – Azafaros B.V. today announced the completion of its 12-week Phase 2 clinical study, RAINBOW (Phase 2 RAINBOW ... |
| 22.01.2024 | Investing in vision: Innovation in retinal therapeutics and the influence on venture capital investment | Publication: Progress in Retinal and Eye Research |
| 02.10.2023 | Fierce Biotech - ‘The fundamentals are really strong’: Why investors are staying loyal to European biotech in 2023 | Fierce Biotech's James Waldron covered the biotech industry with a review to date. He explains that while the biotech bull market hasn’t charged back in 2023 as many had hoped, European-focused venture capital firms don’t seem to have had p... |
| 02.10.2023 | 'The fundamentals are really strong': Why investors are staying loyal to European biotech in 2023 | While the biotech bull market hasn’t charged back in 2023 as many had hoped, European-focused venture capital firms don’t seem to have had problems bringing in money.
In fact, both Forbion and BioGeneration Ventures announced their largest ... |
| 20.07.2023 | Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment | General Partner Rogier Rooswinkel was a contributing author to the article "Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment" published in Nature Communications. Click ... |
| 19.07.2023 | Dutch biotech River BioMedics raises €2M to discover, develop novel cardiac drugs | Read this article in:
Enschede-based River BioMedics, a Dutch biotech company focused on cardiac drug discovery using 3D human cardiac models, announced that it has secured €2M in a seed round of funding.
The Dutch startup aims to progress ... |
| 13.07.2023 | BioGeneration Ventures Closes BGV Fund V, at €150M | BioGeneration Ventures (BGV), a Naarden, The Netherlands-based early-stage VC in European biopharma, closed BGV V, at €150m.
LPs included US institutional investors and corporate investors including Eli Lilly and Company, Novo Holdings and ... |
| 12.07.2023 | Sifted - The 10 most active techbio investors in Europe | Forbion was included in Sifted's list of "The 10 most active techbio investors in Europe". Click here to access the article online. For information on the term "techbio" check out the definition from the UK BioIndustry A... |
| 11.05.2023 | Il mercato del Venture Capital ad aprile 2023 | Come è andato il mercato del Venture Capital ad aprile 2023? Facciamo insieme una carrellata delle startup, delle scaleup e dei round più interessanti. Purtroppo, i dati del primo trimestre 2023 confermano i trend negativi in Europa per gli... |
| 31.03.2023 | Precision Financing | Nature Biotechnology's Melanie Senior writes that private biotech financing in 2023 is more discriminate, disciplined and demanding, and that strong data and efficiency are derigueur. Forbion's Managing Partner Sander Slootweg delivers his ... |
| 28.02.2023 | Life changing treatments for rare disease – a beacon of hope | This article appeared in Labiotech on Rare Disease Day 28 February 2023. Click here to read the online version. The text from the article follows below. |
| 31.01.2023 | BIA Finance Report - Forbion named the most active non-UK investor | The latest UK #biotech investment data collected in collaboration with Clarivate has been published by the UK BioIndustry Association (BIA). Forbion was named the most active non-UK investor in the sector in the BIA’s list of “Top ten VC in... |
| 18.11.2022 | FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance a First-in-Class neuroprotectant | November 17, 2022 |
| 17.11.2022 | Forbion Portfolio Company Inversago named in Labiotech list of "The hottest private biotech companies in Canada" | The hottest private biotech companies in Canada
BY JONATHAN SMITH
NOVEMBER 17, 2022 |
| 26.09.2022 | Amsterdam-based Phosphoenix bags funds to help blind people regain functional vision: Know more | Amsterdam-based Phosphoenix, a company that is working to help blind people regain functional vision even after extensive damage to the eye or optic nerve, announced on Thursday, September 22, that it raised an undisclosed amount of funding... |
| 01.10.2021 | BGV closes $110M fund | Benhamou Global Ventures has raised $110 million for its fourth flagship fund. The Palo Alto-based VC firm invests in cloud-native, AI- and automation-driven companies; its portfolio includes Totango, Flytrex and Virtana.
View fund |
| 30.09.2021 | BGV closes fourth fund with $110M aimed at immigrant enterprise AI, cross-border startups | Silicon Valley-based venture capital (VC) firm Benhamou Global Ventures, known as BGV, closed its fourth fund with $110 million to support global enterprise companies.
The new fund is 60% larger than its third fund and will be invested simi... |
| 09.07.2020 | VarmX raises €32M in Series B financing to develop innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants | 08/07/2020
Press release
VARMX RAISES €32 MILLION IN SERIES B FINANCING TO DEVELOP INNOVATIVE REVERSAL AGENT FOR THE TREATMENT AND PREVENTION OF SEVERE BLEEDING IN PATIENTS ON ORAL ANTICOAGULANTS.
• Financing co-led by Ysios Capital and ... |
| 08.07.2020 | Ysios Capital lidera una inversión de €32M en VarmX | 08/08/2020
Nota de prensa
YSIOS LIDERA UNA INVERSIÓN DE €32 MILLONES EN VARMX.
– VarmX (Leiden,Países Bajos), está desarrollando un fármaco innovador para el tratamiento y prevención de hemorragias graves en pacientes tratados con antico... |
| 29.06.2020 | Tech startups weekly: Uber Green rides, delivery robots at hospitals, funding for edutech, logistics startups | The COVID-19 pandemic prevails after months but businesses across Europe are swinging back to action and adapting to the new normal standards. Despite this phase, many European tech startups are coming up with solutions that will tackle the... |
| 24.06.2020 | Dutch VC BioGeneration Ventures closes €105 million fund for early-stage biotech startups in Europe | BioGeneration Ventures (BGV), an early-stage VC in European biotech, has closed its fourth fund at €105 million, bringing the Dutch firm’s total assets under management above €220 million. Investors in BGV IV include Bristol Myers Squibb, S... |
| 31.07.2019 | BGV Closes $70 Million For Its Opportunity Fund | BGV — an early-stage VC firm with a focus on enterprise 4.0 startups — announced it closed $70 million for the Opportunity Fund
BGV — an early-stage VC firm with deep Silicon Valley roots with a focus on enterprise 4.0 startups in global ma... |
| 25.07.2019 | BGV Completes $70M Opportunity Fund | BGV, a Palo Alto, CA-based early-stage venture capital firm with an exclusive focus on enterprise 4.0 startups in global markets, closed its Opportunity Fund, at $70m.
The Opportunity Fund is designed to make expansion stage investments in ... |
| 01.11.2017 | Term Sheet — Wednesday, November 1 | 5 Qs WITH A DEALMAKER
You may know Cindy Whitehead as the woman behind Addyi, the women’s libido-enhancing pill dubbed “the female Viagra.” After two failed attempts, she finally got the drug through FDA approval and promptly sold the compa... |
| 31.10.2017 | BioGeneration Ventures Closes Third Venture Capital Fund, at €82M | BioGeneration Ventures (BGV), a Naarden, The Netherlands-based venture capital firm with a focus on early stage European biotech, medtech, and diagnostics companies, closed its third fund, at €82m.
New investors in BGV III include biopharma... |
| 31.10.2017 | Bristol-Myers, Johnson & Johnson help BGV top fund goal | Bristol-Myers Squibb and Johnson & Johnson have invested in BioGeneration Ventures’ (BGV) third fund. The involvement of the Big Pharma companies helped BGV blast past its fundraising target, leaving it with €82 million ($95 million) to... |
| 31.10.2017 | Bristol-Myers, Johnson & Johnson help BGV top fund goal | Bristol-Myers Squibb and Johnson & Johnson have invested in BioGeneration Ventures’ (BGV) third fund. The involvement of the Big Pharma companies helped BGV blast past its fundraising target, leaving it with €82 million ($95 million) to... |
| 02.07.2017 | BioGeneration Ventures Fund III Secures €66M | BioGeneration Ventures (BGV), a Naarden, The Netherlands-based early stage life sciences venture capital firm with funds focused on European biotechnology companies, received an additional investment, taking the total capital commitments to... |
| 28.01.2013 | Medisse Closes €2.6M Series B Equity Financing | Medisse B.V., an Ede, the Netherlands-based closed a €2.6m Series B equity financing round.
Backers included new investor IIG, which joined existing investors BioGeneration Ventures and Omnes Capital in the round. In addition, the company w... |
| 28.11.2012 | Lanthio Pharma Raises €4.8M in First Close of Series A funding | Lanthio Pharma B.V., a Groningen, The Netherlands-based biopharmaceutical company focused on discovering and developing a new class of therapeutic peptides with high target selectivity and improved “drug-like” properties, has raised €4.8m i... |
| - | Nou fond de investiții european, de 105 milioane euro, pentru inovații medicale | Firmele europene „early stage” care dezvoltă biotehnologii și alte astfel de inovații în domeniul medical vor putea obține noi finanțări de capital de risc din partea unui fond de investiții de 105 milioane de euro, lansat miercuri.
Fondul ... |
